RARE - Ultragenyx Pharmaceutical Inc.
NEXT EARNINGS:
May 5, 2026
EPS Est: $-1.48
|
Rev Est: $163.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$49.90
DETAILS
HIGH:
$63.00
LOW:
$34.00
MEDIAN:
$50.00
CONSENSUS:
$49.90
UPSIDE:
169.73%
Market Cap:
1.79B
Volume:
3,481,100
Avg Volume:
2,881,954
52 Week Range:
18.29-42.37
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.21
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,294
IPO Date:
2014-01-31
EPS (TTM):
-5.84
P/E Ratio:
-3.94
Revenue (TTM):
672.72M
Total Assets:
1.53B
Total Debt:
1.28B
Cash & Equiv:
434.00M
Rev Growth (5Y):
20.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-46.6%
Debt/Equity:
0.74
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $-1.29 | $-1.20 | -7.5% | $207.0M | $172.0M | +20.3% |
| 2025-11-04 | $-1.81 | $-1.23 | -47.2% | $159.9M | $199.8M | -19.9% |
| 2025-08-05 | $-1.17 | $-1.27 | +7.9% | $166.5M | $165.9M | +0.3% |
| 2025-05-06 | $-1.57 | $-1.54 | -1.9% | $139.3M | $162.4M | -14.2% |
| 2025-02-13 | $-1.39 | $-1.32 | -5.3% | $164.9M | $158.7M | +3.9% |
| 2024-11-05 | $-1.40 | $-1.45 | +3.4% | $139.5M | $146.5M | -4.8% |
| 2024-08-01 | $-1.52 | $-1.64 | +7.3% | $147.0M | $123.2M | +19.4% |
| 2024-05-02 | $-2.03 | $-1.72 | -18.0% | $108.8M | $116.0M | -6.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 673.00M | 560.23M | 434.25M | 363.33M | 351.41M | 271.03M | 103.71M | 51.49M | 2.61M | 133,000 | 0 | 0 |
| Net Income | (575.00M) | (569.18M) | (606.64M) | (707.42M) | (454.02M) | (186.57M) | (402.73M) | (197.61M) | (302.14M) | (245.87M) | (145.62M) | (59.80M) |
| EPS | -5.83 | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 | -7.12 | -3.97 | -7.12 | -6.21 | -3.96 | -2.08 |
| Total Assets | 1.53B | 1.50B | 1.49B | 1.55B | 1.52B | 1.76B | 1.14B | 719.56M | 490.75M | 540.63M | 559.57M | 197.97M |
| Total Debt | 1.28B | 40.34M | 43.17M | 31.59M | 41.97M | 48.23M | 36.99M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 434.00M | 173.73M | 213.58M | 132.94M | 307.58M | 713.53M | 433.58M | 113.43M | 100.49M | 161.12M | 93.57M | 24.32M |
| Operating Cash Flow | (466.00M) | (414.19M) | (474.81M) | (380.46M) | (338.69M) | (132.22M) | (345.38M) | (290.57M) | (253.84M) | (160.97M) | (105.98M) | (44.63M) |
| Free Cash Flow | (472.00M) | (421.68M) | (521.57M) | (526.59M) | (411.79M) | (176.12M) | (370.21M) | (294.64M) | (256.64M) | (171.16M) | (110.93M) | (46.78M) |
| FCF per Share | -4.79 | -4.66 | -7.09 | -7.53 | -6.07 | -2.89 | -6.54 | -5.92 | -6.05 | -4.32 | -3.02 | -1.63 |
| Book Value | (80.00M) | 255.30M | 275.41M | 352.49M | 922.56M | 1.15B | 653.76M | 608.91M | 383.45M | 473.97M | 531.09M | 184.94M |
| Cash & ST Investments | 693.00M | 610.02M | 577.21M | 747.76M | 740.20M | 1.20B | 755.23M | 459.71M | 244.47M | 498.11M | 437.00M | 187.49M |
| ROC Equity | N/A | -2.23 | -2.20 | -2.01 | -0.49 | -0.16 | -0.62 | -0.32 | -0.79 | -0.52 | -0.27 | -0.32 |